News

Explore BioPhotas Inc.'s Groundbreaking Celluma SERIES 2 Devices

Explore BioPhotas Inc.'s Groundbreaking Celluma SERIES 2 Devices

Discovering the Future of Light Therapy: Celluma SERIES 2

BioPhotas Inc. is raising the bar in light therapy technology with their new Celluma SERIES 2 devices. These innovative products mark a major advancement in professional-grade low-level light therapy.

Unmatched Battery-Powered Flexibility

One of the standout features of the SERIES 2 line is its battery-powered functionality. This allows users to enjoy an unprecedented level of mobility and flexibility when using light therapy devices. Designed with a patented flexible shape, these devices ensure a comfortable and effective treatment experience for everyone.

Next-Level Technology for Superior Performance

As Curtis Cluff, CEO of BioPhotas, explains, the new electronics platform is more than just an upgrade—it's a complete reimagining. It's built around a high-performance energy-efficient processor, providing remarkable capabilities through advanced treatment algorithms. This translates to better power distribution and high-quality treatment options for users.

Shared Features Across All Models

The SERIES 2 devices come packed with various innovative features. With lightweight, high-capacity built-in batteries, each device can handle about four 20-minute treatments on a single charge, depending on the selected treatment type. The LED charge status indicator makes it easy to see when it's time for a recharge, simplifying treatment management.

User-Friendly Design

The new compact controller design enhances the usability of the SERIES 2 devices. Featuring a digital timer that tracks treatment duration, users can effortlessly manage their sessions. Plus, the pause feature allows users to pause and then safely resume treatments, ensuring that every session hits the desired length.

Affordable Accessibility for Everyone

In an exciting announcement, BioPhotas revealed that the Celluma SERIES 2 devices will retain the same affordable price as the previous models. This translates into a savings of $200 compared to older models that included battery support, making advanced light therapy more attainable for a broader audience.

Diverse Treatment Options

BioPhotas is committed to addressing a variety of needs with their light therapy devices. The SERIES 2 line includes models tailored for different skin concerns, such as acne, aging skin, and muscle pain. Each model offers specific treatment modes, allowing users to choose the device that best suits their individual needs.

About BioPhotas, Inc.

BioPhotas, Inc. has established itself as a leader in innovative light therapy devices. Based on NASA-developed technology and backed by clinical evidence, the company provides reliable and effective solutions for healthcare professionals and everyday consumers alike. The Celluma SERIES makes the benefits of low-level light therapy easily accessible for users in their homes or practices.

Frequently Asked Questions

What is the Celluma SERIES 2?

The Celluma SERIES 2 is BioPhotas' next-generation line of low-level light therapy devices designed for better mobility and treatment efficiency.

What benefits do Celluma devices offer?

These devices provide safe and effective treatment options for various skin and muscle conditions, utilizing advanced technology to achieve optimal results.

Are the SERIES 2 devices battery-operated?

Yes, the SERIES 2 models feature built-in batteries, making mobility during treatment sessions effortless.

How does the new electronics platform enhance performance?

The upgraded electronics platform includes an energy-efficient processor that improves treatment capabilities and optimizes power management.

Where can I find more information about BioPhotas and its products?

More details can be found on the BioPhotas website, which highlights all their light therapy devices and their respective benefits.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Penarth Master Issuer: Key Changes to £600M Floating Notes

Updated Category News Views 226

Understanding the Recent Amendments by Penarth Master Issuer Penarth Master Issuer PLC has made noteworthy adjustments to its £600 million asset-backed floating notes, which were initially set to mature in 2021 and have now been extended to 2025. Set to take effect from the next interest payment date in January 2025, these changes involve an extension of the redemption...

Continue Reading
RAMM Pharma Corp. Strategizes Potential Sale of Canapar

Updated Category News Views 143

RAMM Pharma Corp. Explores Strategic Sale Options RAMM Pharma Corp. (CSE: RAMM), along with its wholly owned subsidiaries, is considering the sale of its subsidiary, Canapar Corp., and its industrial facility situated in Italy. This strategy aligns with the Company’s goal of enhancing operational efficiency and focusing on growth avenues in the cannabinoid industry....

Continue Reading
Broadridge Financial Solutions Announces Significant Dividend Payout

Updated Category News Views 135

Broadridge Financial Solutions Announces Quarterly Dividend NEW YORK — Broadridge Financial Solutions, Inc. (NYSE: BR) has recently declared a quarterly cash dividend of $0.975 per share. This announcement is a commitment to delivering shareholder value and reflects the company’s ongoing performance and stability in the financial services sector. Details of the...

Continue Reading
Coral Vita Champions Ocean Restoration at NYC Climate Week

Updated Category News Views 169

Coral Vita's Inspirational Event at Climate Week In a remarkable showcase of commitment to ocean conservation, Coral Vita, recognized globally for its pioneering efforts in commercial land-based coral reef restoration, led an event called "Currents." This full-day gathering took place during NYC Climate Week and served as a melting pot for climate action intertwined with...

Continue Reading
Major Hydropower Initiative on the Tibetan Plateau Unveiled

Updated Category News Views 277

China's Ambitious Hydropower Dam Project in Tibet China has recently given the green light for the construction of what promises to be the world's largest hydropower dam, marking a significant milestone for energy production on the Tibetan plateau. This ambitious initiative, situated on the eastern edge of Tibet, has the potential to impact millions of individuals...

Continue Reading